Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 8/2007

01.08.2007 | Original Article

Mechanism of antitumor effect on mouse hepatocellular carcinoma by intratumoral injection of OK-432, a streptococcal preparation

verfasst von: Sadamu Homma, Yukiko Sagawa, Hideo Komita, Shigeo Koido, Eijiro Nagasaki, Yoshiki Ryoma, Masato Okamoto

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 8/2007

Einloggen, um Zugang zu erhalten

Abstract

Intratumoral (i.t.) injection of OK-432, a streptococcal preparation, into implanted tumors of mouse hepatocellular carcinoma (MIH-2) showed antitumor effect including tumor eradication. Intraperitoneal administration of same dose OK-432 did not exhibit tumor suppressive effect. In vitro cytotoxic test suggested that direct cytotoxic effect of OK-432 was not associated with antitumor activity by i.t.-OK-432 treatment. It was also found that Toll-like receptor 4 signaling was not involved in i.t.-OK-432 treatment. Three mice out of five, which had shown tumor eradication by i.t.-OK-432 treatment did not reject re-challenge of MIH-2 cells. Splenocytes from i.t.-OK-432 treated mice did not produce IFN-gamma by stimulation with MIH-2 cells in vitro, but produced abundant IFN-gamma by stimulation with OK-432. Immunofluorescence microscopy demonstrated that CD4+T cells, but not CD8+T cells, infiltrated to i.t.-OK-432 treated tumor tissue produced IFN-gamma. Tumor-infiltrating CD4+T cells from i.t.-OK-432 treated tumor tissue produced IFN-gamma by in vitro stimulation with OK-432 higher than those from untreated tumor tissue. IFN-gamma directly induced apoptosis of MIH-2 cells in vitro. Collectively, i.t.-OK-432 treatment induced priming of CD4+T cells to antigenecity of OK-432, and repetitive i.t.-OK-432 treatment induced IFN-gamma production from OK-432-sensitized CD4+T cells in tumor site, leading to apoptosis of MIH-2 cells susceptible to IFN-gamma.
Literatur
1.
Zurück zum Zitat Maehara Y, Okuyama T, Kakeji Y, Baba H, Furusawa M, Sugimachi K (1994) Postoperative immunochemotherapy including streptococcal lysate OK-432 is effective for patients with gastric cancer and serosal invasion. Am J Surg 168:36–40PubMedCrossRef Maehara Y, Okuyama T, Kakeji Y, Baba H, Furusawa M, Sugimachi K (1994) Postoperative immunochemotherapy including streptococcal lysate OK-432 is effective for patients with gastric cancer and serosal invasion. Am J Surg 168:36–40PubMedCrossRef
2.
Zurück zum Zitat Kim SY, Park HC, Yoon C, Yoon HJ, Choi YM, Cho KS (1998) OK-432 and 5-fluorouracil, doxorubicin, and mitomycin C (FAM-P) versus FAM chemotherapy in patients with curatively resected gastric carcinoma: a randomized phase III trial. Cancer 83:2054–2059PubMedCrossRef Kim SY, Park HC, Yoon C, Yoon HJ, Choi YM, Cho KS (1998) OK-432 and 5-fluorouracil, doxorubicin, and mitomycin C (FAM-P) versus FAM chemotherapy in patients with curatively resected gastric carcinoma: a randomized phase III trial. Cancer 83:2054–2059PubMedCrossRef
3.
Zurück zum Zitat Ikehara M, Oshita F, Suzuki R, Saitoh H, Yamada K, Noda K (2004) Phase II study of OK-432 intrapleural administration followed by systemic cisplatin and gemcitabine for non-small cell lung cancer with pleuritis carcinomatosa. J Exp Ther Oncol 4:79–83PubMed Ikehara M, Oshita F, Suzuki R, Saitoh H, Yamada K, Noda K (2004) Phase II study of OK-432 intrapleural administration followed by systemic cisplatin and gemcitabine for non-small cell lung cancer with pleuritis carcinomatosa. J Exp Ther Oncol 4:79–83PubMed
4.
Zurück zum Zitat Kai S, Tanaka J, Nomoto K, Torisu M (1979) Studies on the immunopotentiating effects of a streptococcal preparation, OK-432. I. Enhancement of T cell-mediated immune responses of mice. Clin Exp Immunol 37:98–105PubMed Kai S, Tanaka J, Nomoto K, Torisu M (1979) Studies on the immunopotentiating effects of a streptococcal preparation, OK-432. I. Enhancement of T cell-mediated immune responses of mice. Clin Exp Immunol 37:98–105PubMed
5.
Zurück zum Zitat Oshimi K, Kano S, Takaku F, Okumura K (1980) Augmentation of mouse natural killer cell activity by a streptococcal preparation, OK-432. J Natl Cancer Inst 65:1265–1269PubMed Oshimi K, Kano S, Takaku F, Okumura K (1980) Augmentation of mouse natural killer cell activity by a streptococcal preparation, OK-432. J Natl Cancer Inst 65:1265–1269PubMed
6.
Zurück zum Zitat Fujimoto T, Duda RB, Szilvasi A, Chen X, Mai M, O’Donnell MA (1997) Streptococcal preparation OK-432 is a potent inducer of IL-12 and a T helper cell 1 dominant state. J Immunol 158:5619–5626PubMed Fujimoto T, Duda RB, Szilvasi A, Chen X, Mai M, O’Donnell MA (1997) Streptococcal preparation OK-432 is a potent inducer of IL-12 and a T helper cell 1 dominant state. J Immunol 158:5619–5626PubMed
7.
Zurück zum Zitat Okamoto M, Oshikawa T, Tano T, Ahmed SU, Kan S, Sasai A, Akashi S, Miyake K, Moriya Y, Ryoma Y, Saito M, Sato M (2006) Mechanism of anticancer host response induced by OK-432, a streptococcal preparation, mediated by phagocytosis and Toll-like receptor 4 signaling. J Immunother 29:78–86PubMedCrossRef Okamoto M, Oshikawa T, Tano T, Ahmed SU, Kan S, Sasai A, Akashi S, Miyake K, Moriya Y, Ryoma Y, Saito M, Sato M (2006) Mechanism of anticancer host response induced by OK-432, a streptococcal preparation, mediated by phagocytosis and Toll-like receptor 4 signaling. J Immunother 29:78–86PubMedCrossRef
8.
Zurück zum Zitat Okamoto M, Ohe G, Oshikawa T, Nishikawa H, Furuichi S, Yoshida H, Matsuno T, Saito M, Sato M (2000) Induction of Th1-type cytokines by lipoteichoic acid-related preparation isolated from OK-432, a penicillin-killed streptococcal agent. Immunopharmacology 49:363–376PubMedCrossRef Okamoto M, Ohe G, Oshikawa T, Nishikawa H, Furuichi S, Yoshida H, Matsuno T, Saito M, Sato M (2000) Induction of Th1-type cytokines by lipoteichoic acid-related preparation isolated from OK-432, a penicillin-killed streptococcal agent. Immunopharmacology 49:363–376PubMedCrossRef
9.
Zurück zum Zitat Okamoto M, Furuichi S, Nishioka Y, Oshikawa T, Tano T, Ahmed SU, Takeda K, Akira S, Ryoma Y, Moriya Y, Saito M, Sone S, Sato M (2004) Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation. Cancer Res 64:5461–5470PubMedCrossRef Okamoto M, Furuichi S, Nishioka Y, Oshikawa T, Tano T, Ahmed SU, Takeda K, Akira S, Ryoma Y, Moriya Y, Saito M, Sone S, Sato M (2004) Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation. Cancer Res 64:5461–5470PubMedCrossRef
10.
Zurück zum Zitat Watanabe M, Nishida O, Kunii Y, Kodaira S, Takahashi T, Tominaga T, Hojyo K, Kato T, Niimoto M, Kunitomo K, Isomoto H, Ohashi Y, Yasutomi M (2004) Randamized controlled trial of the efficacy of adjuvant immunochemotherapy and adjuvant chemotherapy for colorectal cancer, using different combinations of the intracutaneous streptococcal preparation OK-432 and the oral pyrimidines 1-hexylcarbamoyl-5-fluorouracil and uracil/tegafur. Int J Clin Oncol 9:98–106PubMedCrossRef Watanabe M, Nishida O, Kunii Y, Kodaira S, Takahashi T, Tominaga T, Hojyo K, Kato T, Niimoto M, Kunitomo K, Isomoto H, Ohashi Y, Yasutomi M (2004) Randamized controlled trial of the efficacy of adjuvant immunochemotherapy and adjuvant chemotherapy for colorectal cancer, using different combinations of the intracutaneous streptococcal preparation OK-432 and the oral pyrimidines 1-hexylcarbamoyl-5-fluorouracil and uracil/tegafur. Int J Clin Oncol 9:98–106PubMedCrossRef
11.
Zurück zum Zitat Toge T, Kininobu H, Yamaguchi Y, Baba N, Kegoya Y, Hatton T (1988) The clinical efficacy of intratumoral OK-432 administration in advanced cancer patients. Jpn J Surg 18:668–674PubMedCrossRef Toge T, Kininobu H, Yamaguchi Y, Baba N, Kegoya Y, Hatton T (1988) The clinical efficacy of intratumoral OK-432 administration in advanced cancer patients. Jpn J Surg 18:668–674PubMedCrossRef
12.
Zurück zum Zitat Monden T, Morimoto H, Shimano T, Yagyu T, Murotani M, Nagaowa H, Kawasaki Y, Kobayashi T, Mori T (1992) Use of fibrinogen to enhance the antitumor effect of OK-432-A new approach to immunotherapy for colorectal carcinoma. Cancer 69:636–642PubMedCrossRef Monden T, Morimoto H, Shimano T, Yagyu T, Murotani M, Nagaowa H, Kawasaki Y, Kobayashi T, Mori T (1992) Use of fibrinogen to enhance the antitumor effect of OK-432-A new approach to immunotherapy for colorectal carcinoma. Cancer 69:636–642PubMedCrossRef
13.
Zurück zum Zitat Nakazawa S, Yoshino J, Okumura S, Yamao K (1988) Clinical efficacy of endoscopic injection of OK-432 in the treatment of gastric cancer. Scand J Gastroenterol 23:539–545PubMed Nakazawa S, Yoshino J, Okumura S, Yamao K (1988) Clinical efficacy of endoscopic injection of OK-432 in the treatment of gastric cancer. Scand J Gastroenterol 23:539–545PubMed
14.
Zurück zum Zitat Tanaka N, Gouchi A, Ohara T, Mannami T, Konaga E, Fuchimoto S, Okumura S, Sato K, Orita K (1994) Intratumoral injection of a streptococcal preparation , OK-432, before surgery for gastric cancer. A randomized trial. Cooperative Study Group of preoperative intratumoral immunotherapy for cancer. Cancer 74:3097–3103PubMedCrossRef Tanaka N, Gouchi A, Ohara T, Mannami T, Konaga E, Fuchimoto S, Okumura S, Sato K, Orita K (1994) Intratumoral injection of a streptococcal preparation , OK-432, before surgery for gastric cancer. A randomized trial. Cooperative Study Group of preoperative intratumoral immunotherapy for cancer. Cancer 74:3097–3103PubMedCrossRef
15.
Zurück zum Zitat Himoto T, Watanabe S, Nishioka M, Maeba T, Tanaka S, Saito M (1996) Combination immunotherapy with OK-432, recombinant granulocyte-colony-stimulating factor and recombinant interleukin-2 for human hepatocellular carcinoma. Cancer Immunol Immunother 42:127–131PubMedCrossRef Himoto T, Watanabe S, Nishioka M, Maeba T, Tanaka S, Saito M (1996) Combination immunotherapy with OK-432, recombinant granulocyte-colony-stimulating factor and recombinant interleukin-2 for human hepatocellular carcinoma. Cancer Immunol Immunother 42:127–131PubMedCrossRef
16.
Zurück zum Zitat Suto T, Fukuda S, Moriya N, Watanabe Y, Sasaki D, Yoshida Y, Sakata Y (1994) Clinical study of biological response modifiers as maintenance therapy for hepatocellular carcinoma. Cancer Chemother Pharmacol 33(Suppl):S145–S148PubMedCrossRef Suto T, Fukuda S, Moriya N, Watanabe Y, Sasaki D, Yoshida Y, Sakata Y (1994) Clinical study of biological response modifiers as maintenance therapy for hepatocellular carcinoma. Cancer Chemother Pharmacol 33(Suppl):S145–S148PubMedCrossRef
17.
Zurück zum Zitat Okamoto M, Oshikawa T, Tano T, Sasai A, Kan S, Hiroshima T, Ohue H, Moriya Y, Ryoma Y, Saito M, Sato M (2004) Anti-tumor effect of an intratumoral administration of dendritic cells in combination with TS-1, an oral fluoropyrimidine anti-cancer drug, and OK-432, a streptococcal immunopotentiator: involvement of toll-like receptor 4. J Immunother 27:432–441PubMedCrossRef Okamoto M, Oshikawa T, Tano T, Sasai A, Kan S, Hiroshima T, Ohue H, Moriya Y, Ryoma Y, Saito M, Sato M (2004) Anti-tumor effect of an intratumoral administration of dendritic cells in combination with TS-1, an oral fluoropyrimidine anti-cancer drug, and OK-432, a streptococcal immunopotentiator: involvement of toll-like receptor 4. J Immunother 27:432–441PubMedCrossRef
18.
Zurück zum Zitat Irie M, Homma S, Komita H, Zeniya M, Kufe D, Ohno T, Toda G (2004) Inhibitio of spontaneous development of liver tumors by inoculation with dendritic cells loaded with hepatocellular carcinoma cells in C3H/HeNCrj mice. Int J Cancer 111:238–245PubMedCrossRef Irie M, Homma S, Komita H, Zeniya M, Kufe D, Ohno T, Toda G (2004) Inhibitio of spontaneous development of liver tumors by inoculation with dendritic cells loaded with hepatocellular carcinoma cells in C3H/HeNCrj mice. Int J Cancer 111:238–245PubMedCrossRef
19.
Zurück zum Zitat Homma S, Toda G, Gong J, Kufe D, Ohno T (2001) Preventive antitumor activity against hepatocellular carcinoma (HCC) induced by immunozation with fusions of dendritic cells and HCC cells in mice. J Gastroenterol 36:764–771PubMedCrossRef Homma S, Toda G, Gong J, Kufe D, Ohno T (2001) Preventive antitumor activity against hepatocellular carcinoma (HCC) induced by immunozation with fusions of dendritic cells and HCC cells in mice. J Gastroenterol 36:764–771PubMedCrossRef
20.
Zurück zum Zitat Homma S, Komita H, Sagawa Y, Ohno T, Toda G (2005) Antitumor activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12. Immunology 115:451–461PubMedCrossRef Homma S, Komita H, Sagawa Y, Ohno T, Toda G (2005) Antitumor activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12. Immunology 115:451–461PubMedCrossRef
21.
Zurück zum Zitat Nio Y, Zighelboim J, Berek J, Bonavida B (1989) Cytotoxic and cytostatic effects of the streptococcal preparation OK-432 and its subcellular fraction on human ovarian tumor cells. Cancer 64:434–441PubMedCrossRef Nio Y, Zighelboim J, Berek J, Bonavida B (1989) Cytotoxic and cytostatic effects of the streptococcal preparation OK-432 and its subcellular fraction on human ovarian tumor cells. Cancer 64:434–441PubMedCrossRef
22.
Zurück zum Zitat Nakahara S, Tsunoda T, Baba T, Asabe S, Tahara H (2003) Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide. Cancer Res 63:4112–4118PubMed Nakahara S, Tsunoda T, Baba T, Asabe S, Tahara H (2003) Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide. Cancer Res 63:4112–4118PubMed
23.
Zurück zum Zitat Komita H, Homma S, Saotome H, Zeniya M, Ohno T, Toda G (2006) Interferon-gamma produced by interleukin-12-activated tumor infiltrating CD8+T cells directly induces apoptosis of mouse hepatocellular carcinoma. J Hepatol 45:662–672PubMedCrossRef Komita H, Homma S, Saotome H, Zeniya M, Ohno T, Toda G (2006) Interferon-gamma produced by interleukin-12-activated tumor infiltrating CD8+T cells directly induces apoptosis of mouse hepatocellular carcinoma. J Hepatol 45:662–672PubMedCrossRef
Metadaten
Titel
Mechanism of antitumor effect on mouse hepatocellular carcinoma by intratumoral injection of OK-432, a streptococcal preparation
verfasst von
Sadamu Homma
Yukiko Sagawa
Hideo Komita
Shigeo Koido
Eijiro Nagasaki
Yoshiki Ryoma
Masato Okamoto
Publikationsdatum
01.08.2007
Verlag
Springer-Verlag
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 8/2007
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-006-0277-9

Weitere Artikel der Ausgabe 8/2007

Cancer Immunology, Immunotherapy 8/2007 Zur Ausgabe

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.